Novel therapeutic approaches in pulmonary arterial hypertension: Focus on tadalafil

Drugs of Today

Volumn 47, Issue 2, 2011, Pages 145-156

  Levin, Y D ^a   White, R James ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANOREXIGENIC AGENT; BOSENTAN; CILOSTAZOL; CYCLIC GMP; DIPYRIDAMOLE; ENDOTHELIN 1; MILRINONE; NITRIC OXIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; ROFLUMILAST; SILDENAFIL; TADALAFIL; THEOPHYLLINE; THROMBOXANE A2; VARDENAFIL;

BACKACHE; BLEEDING; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOXIA; IDIOPATHIC DISEASE; ISCHEMIC OPTIC NEUROPATHY; KIDNEY FAILURE; LUNG ARTERY PRESSURE; LUNG DISEASE; MYALGIA; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VISUAL DISORDER;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBOLINES; HUMANS; HYPERTENSION, PULMONARY; KIDNEY; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SIGNAL TRANSDUCTION; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 79955920960     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.2.1544337     Document Type: Review

References (46)

1. McLaughlin, V.V., Archer, S.L., Badesch, D.B. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation 2009, 119(16): 2250-94.
2. Simonneau, G., Robbins, I.M., Beghetti, M. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(1 Suppl): S43-54.
3. Hoeper, M.M., Barbera, J.A., Channick, R.N. et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009, 54(1 Suppl): S85-96.
4. Humbert, M., Sitbon, O., Chaouat, A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173(9): 1023-30.
5. DAlonzo, G.E., Barst, R.J., Ayres, S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115(5): 343-9.
6. Kawut, S.M., Horn, E.M., Berekashvili, K.K. et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005, 95(2): 199-203. (Pubitemid 40092084)
7. Shah, S.J., Thenappan, T., Rich, S., Tian, L., Archer, S.L., Gomberg-Maitland, M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008, 117(19): 2475-83. (Pubitemid 351670454)
8. Badesch, D.B., Raskob, G.E., Elliott, C.G. et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137(2): 376-87.
9. Humbert, M., Morrell, N.W., Archer, S.L. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl. S): 13S-24S.
10. Newman, J.H., Fanburg, B.L., Archer, S.L. et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004, 109(24): 2947-52.
11. Giaid, A., Saleh, D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333(4): 214-21.
12. Xu, W., Kaneko, F.T., Zheng, S. et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004, 18(14): 1746-8. (Pubitemid 39561671)
13. Wharton, J., Strange, J.W., Moller, G.M. et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172(1): 105-13. (Pubitemid 40923321)
14. Archer, S.L., Djaballah, K., Humbert, M. et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998, 158(4): 1061-7. (Pubitemid 28489002)
15. Ghofrani, H.A., Pepke-Zaba, J., Barbera, J.A. et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl. S): 68S-72S.
16. Michelakis, E.D. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev 2003, 8(1): 5-21. (Pubitemid 36342286)
17. Surapisitchat, J., Beavo, J.A. Phosphodiesterase Families. In: Handbook of Cell Signaling (Second Edition). A.B. Ralph, A.D. Edward (Eds.). Academic Press: San Diego 2010, 1409-14.
18. Manganiello, V.C., Degerman, E. Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb Haemost 1999, 82(2): 407-11.
19. Hebb, A.L.O., Robertson, H.A. PDEs as drug targets for CNS immune disorders. Curr Opin Investig Drugs 2008, 9(7): 744-53. (Pubitemid 351950871)
20. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109(3): 366-98. (Pubitemid 43132818)
21. Movsesian, M., Stehlik, J., Vandeput, F., Bristow, M.R. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2009, 14(4): 255-63.
22. Kim, H.H., Liao, J.K. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008, 28(3): s39-42.
23. Field, S.K. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma. Expert Opin investig Drugs 2008, 17(5): 811-8.
24. Boswell-Smith, V., Spina, D., Page, C.P. Phosphodiesterase inhibitors. Br J Pharmacol 2006, 147(Suppl. 1): S252-7.
25. Laties, A.M. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf 2009, 32(1): 1-18.
26. Wilson, L.S., Elbatarny, H.S., Crawley, S.W., Bennett, B.M., Maurice, D.H. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci U S A 2008, 105(36): 13650-5.
27. Herve, P., Humbert, M., Sitbon, O. et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001, 22(3): 451-8.
28. Kumar, P., Francis, G.S., Tang, W.H.W. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nat Rev Cardiol 2009, 6(5): 349-55.
29. Evaluating the effectiveness of sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (The RELAX Study) (NCT00763867). ClinicalTrials.gov Web site, Accessed January 21, 2011.
30. Ballard, S.A., Gingell, C.J., Tang, K., Turner, L.A., Price, M.E., Naylor, A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998, 159(6): 2164-71. (Pubitemid 29190800)
31. Gonzalez, C.M., Bervig, T., Podlasek, C., Huang, C.F., McKenna, K.E., McVary, K.T. Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina. Int J Impot Res 1999, 11(Suppl. 1): S9-14.
32. Bischoff, E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004, 16(Suppl. 1): S11-4.
33. Corbin, J.D., Beasley, A., Blount, M.A., Francis, S.H. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 2005, 334(3): 930-8. (Pubitemid 41033209)
34. Prasad, S., Wilkinson, J., Gatzoulis, M.A. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000, 343(18): 1342.
35. Sastry, B.K., Narasimhan, C., Reddy, N.K., Raju, B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.[see comment]. J Am Coll Cardiol 2004, 43(7): 1149-53. (Pubitemid 38452588)
36. Galie, N., Ghofrani, H.A., Torbicki, A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353(20): 2148-57. (Pubitemid 41653106)
37. Ghofrani, H.A., Voswinckel, R., Reichenberger, F. et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterases inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004, 44(7): 1488-96. (Pubitemid 39303954)
38. Galie, N., Brundage, B.H., Ghofrani, H.A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119(22): 2894-903.
39. McLaughlin, V.V., Benza, R.L., Rubin, L.J. et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55(18): 1915-22.
40. McLaughlin, V.V., Oudiz, R.J., Frost, A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174(11): 1257-63. (Pubitemid 44924827)
41. McKenna, S.P., Doughty, N., Meads, D.M., Doward, L.C., Pepke-Zaba, J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006, 15(1): 103-15. (Pubitemid 43097591)
42. Gomberg-Maitland, M., Thenappan, T., Rizvi, K., Chandra, S., Meads, D.M., McKenna, S.P. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008, 27(1): 124-30.
43. Chakinala, M.M. Evaluating recent therapeutic trials in pulmonary arterial hypertension: Raising the bar for clinical investigation. Adv Pulm Hypertens 2009, 8(1): 24-31.
44. McLaughlin, V.V., Sitbon, O., Badesch, D.B. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25(2): 244-9. (Pubitemid 40246523)
45. Rubin, L.J., Badesch, D.B., Barst, R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12): 896-903. (Pubitemid 34984638)
46. McLaughlin, V.V., McGoon, M.D. Pulmonary arterial hypertension. Circulation 2006, 114(13): 1417-31.